FEATURED COMPANIES
- Addex Therapeutics Ltd
- Astraea Therapeutics LLC
- Consegna Pharma Inc
- Denovo Biopharma LLC
- Kdac Therapeutics Inc
- NLS Pharma Group
The 2020 Drug Addiction pipeline report presents a comprehensive overview of the research and development of Drug Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, 26 drugs in Pre-clinical phase, ten drugs in Phase 1, and Eight drugs in Phase 2.
As of February 2020, the Drug Addiction pipeline remains robust with 48 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Drug Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT1A receptor agonist; 5-HT2B receptor antagonist; Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 3 Beta 4 nicotinic receptor antagonists; Cannabinoid receptor agonists; Cannabinoid receptor CB1 antagonists; Corticotropin releasing hormone inhibitors; CYSLTR1 antagonist; Dopamine Receptors agonist; dopamine transporter inhibitor; Dopamine uptake inhibitors; FAAH (Fatty Acid Amide Hydrolase) inhibitor; GABA A receptor agonists; Glucocorticoid receptor antagonists; GABA B receptor modulators; gamma opioid antagonist; HDAC3 protein inhibitors; kappa-opioid receptor antagonist; metabotropic glutamate receptor 2 agonist; metabotropic glutamate receptor 3 agonist; Metabotropic glutamate receptor 4 agonists; metabotropic glutamate receptor 5 antagonist; Mu Opiate Receptors agonist; Nicotinic receptor antagonists; noradrenaline transporter inhibitor; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Orexin receptor 1 antagonists; oxytocin receptor agonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; Serotonin Receptors agonist; serotonin transporter inhibitor; Serotonin uptake inhibitors; Trace Amine-Associated Receptor 1 Agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Drug Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Drug Addiction pipeline companies included in the report are: Addex Therapeutics Ltd, Aelis Farma SAS, Amygdala Neurosciences Inc, Aphios Corp, Astellas Pharma Inc, Astraea Therapeutics LLC, BioCorRx Inc, Camino Pharma LLC, Charleston Laboratories Inc, Chiesi Farmaceutici SpA, Consegna Pharma Inc, Curemark LLC, Daya Drug Discoveries Inc, DD Therapeutics LLC, Denovo Biopharma LLC, Embera NeuroTherapeutics Inc, EncepHeal Therapeutics Inc, Eolas Therapeutics Inc, F. Hoffmann-La Roche Ltd, Foresee Pharmaceuticals Co Ltd, IMV Inc, InterveXion Therapeutics LLC, Intra-Cellular Therapies Inc, Kdac Therapeutics Inc, KemPharm Inc, Kinoxis Therapeutics Pty Ltd, Kyorin Pharmaceutical Co Ltd, MAKScientific LLC, Mind Medicine Inc, NLS Pharma Group, Novartis AG, Omeros Corp, Orexigen Therapeutics Inc, Paion AG , Protagenic Therapeutics Inc, Saniona AB, Sen-Jam Pharmaceutical LLC , Seropeutics LLC, Sosei Heptares, SpringWorks Therapeutics LLC, Tonix Pharmaceuticals Holding Corp, Tonix Pharmaceuticals Holding Corp , Zelda Therapeutics Pty Ltd , Zyla Life Sciences, Zynerba Pharmaceuticals Inc.
Drug Addiction pipeline drugs profiled in the report include: ADX-88178, AEF0117, ANS-6637, APH-0802 (dronabinol), ASP8062, AT-076, AT-1001, AT-121, BICX-102, SBP-0069330, Small Molecules for Drug Abuse, buprenorphine, naloxone, CM-1212, DDD-024, oxytocin, DB103 (pomaglumetad methionil), EMB-001 (metyrapone + oxazepam), dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction, EORA101, RO5256390, FP-004, Vaccine for Cocaine Abuse, IXT-m200, ITI-333, KDAC-0001, KP879, KNX100 (SOC-1), ibudilast, AM4113, 18-MC, NLS-10, mavoglurant, OMS527, OREX-1038, OREX-1019, remimazolam , PT00114, NS-2359, Exulta-005, SERx-480, Orexin OX1 Antagonists for Addiction, PF 04457845, RBP8000, TNX-1300, Cannabinoid receptor agonists , oxycodone hydrochloride, ZYN002 (cannabidiol)
As of February 2020, the Drug Addiction pipeline remains robust with 48 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Drug Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT1A receptor agonist; 5-HT2B receptor antagonist; Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 3 Beta 4 nicotinic receptor antagonists; Cannabinoid receptor agonists; Cannabinoid receptor CB1 antagonists; Corticotropin releasing hormone inhibitors; CYSLTR1 antagonist; Dopamine Receptors agonist; dopamine transporter inhibitor; Dopamine uptake inhibitors; FAAH (Fatty Acid Amide Hydrolase) inhibitor; GABA A receptor agonists; Glucocorticoid receptor antagonists; GABA B receptor modulators; gamma opioid antagonist; HDAC3 protein inhibitors; kappa-opioid receptor antagonist; metabotropic glutamate receptor 2 agonist; metabotropic glutamate receptor 3 agonist; Metabotropic glutamate receptor 4 agonists; metabotropic glutamate receptor 5 antagonist; Mu Opiate Receptors agonist; Nicotinic receptor antagonists; noradrenaline transporter inhibitor; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Orexin receptor 1 antagonists; oxytocin receptor agonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; Serotonin Receptors agonist; serotonin transporter inhibitor; Serotonin uptake inhibitors; Trace Amine-Associated Receptor 1 Agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Drug Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Drug Addiction development
- Drug Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Drug Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Drug Addiction pipeline candidates included
- Business overview and snapshot of all companies involved in Drug Addiction pipeline are included
- Latest market and pipeline developments are provided in the report
Drug Addiction pipeline companies included in the report are: Addex Therapeutics Ltd, Aelis Farma SAS, Amygdala Neurosciences Inc, Aphios Corp, Astellas Pharma Inc, Astraea Therapeutics LLC, BioCorRx Inc, Camino Pharma LLC, Charleston Laboratories Inc, Chiesi Farmaceutici SpA, Consegna Pharma Inc, Curemark LLC, Daya Drug Discoveries Inc, DD Therapeutics LLC, Denovo Biopharma LLC, Embera NeuroTherapeutics Inc, EncepHeal Therapeutics Inc, Eolas Therapeutics Inc, F. Hoffmann-La Roche Ltd, Foresee Pharmaceuticals Co Ltd, IMV Inc, InterveXion Therapeutics LLC, Intra-Cellular Therapies Inc, Kdac Therapeutics Inc, KemPharm Inc, Kinoxis Therapeutics Pty Ltd, Kyorin Pharmaceutical Co Ltd, MAKScientific LLC, Mind Medicine Inc, NLS Pharma Group, Novartis AG, Omeros Corp, Orexigen Therapeutics Inc, Paion AG , Protagenic Therapeutics Inc, Saniona AB, Sen-Jam Pharmaceutical LLC , Seropeutics LLC, Sosei Heptares, SpringWorks Therapeutics LLC, Tonix Pharmaceuticals Holding Corp, Tonix Pharmaceuticals Holding Corp , Zelda Therapeutics Pty Ltd , Zyla Life Sciences, Zynerba Pharmaceuticals Inc.
Drug Addiction pipeline drugs profiled in the report include: ADX-88178, AEF0117, ANS-6637, APH-0802 (dronabinol), ASP8062, AT-076, AT-1001, AT-121, BICX-102, SBP-0069330, Small Molecules for Drug Abuse, buprenorphine, naloxone, CM-1212, DDD-024, oxytocin, DB103 (pomaglumetad methionil), EMB-001 (metyrapone + oxazepam), dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction, EORA101, RO5256390, FP-004, Vaccine for Cocaine Abuse, IXT-m200, ITI-333, KDAC-0001, KP879, KNX100 (SOC-1), ibudilast, AM4113, 18-MC, NLS-10, mavoglurant, OMS527, OREX-1038, OREX-1019, remimazolam , PT00114, NS-2359, Exulta-005, SERx-480, Orexin OX1 Antagonists for Addiction, PF 04457845, RBP8000, TNX-1300, Cannabinoid receptor agonists , oxycodone hydrochloride, ZYN002 (cannabidiol)
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Addex Therapeutics Ltd
- Astraea Therapeutics LLC
- Consegna Pharma Inc
- Denovo Biopharma LLC
- Kdac Therapeutics Inc
- NLS Pharma Group
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Note: Product cover images may vary from those shown
- Addex Therapeutics Ltd
- Aelis Farma SAS
- Amygdala Neurosciences Inc
- Aphios Corp
- Astellas Pharma Inc
- Astraea Therapeutics LLC
- BioCorRx Inc
- Camino Pharma LLC
- Charleston Laboratories Inc
- Chiesi Farmaceutici SpA
- Consegna Pharma Inc
- Curemark LLC
- Daya Drug Discoveries Inc
- DD Therapeutics LLC
- Denovo Biopharma LLC
- Embera NeuroTherapeutics Inc
- EncepHeal Therapeutics Inc
- Eolas Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- IMV Inc
- InterveXion Therapeutics LLC
- Intra-Cellular Therapies Inc
- Kdac Therapeutics Inc
- KemPharm Inc
- Kinoxis Therapeutics Pty Ltd
- Kyorin Pharmaceutical Co Ltd
- MAKScientific LLC
- Mind Medicine Inc
- NLS Pharma Group
- Novartis AG
- Omeros Corp
- Orexigen Therapeutics Inc
- Paion AG
- Protagenic Therapeutics Inc
- Saniona AB
- Sen-Jam Pharmaceutical LLC
- Seropeutics LLC
- Sosei Heptares
- SpringWorks Therapeutics LLC
- Tonix Pharmaceuticals Holding Corp
- Tonix Pharmaceuticals Holding Corp
- Zelda Therapeutics Pty Ltd
- Zyla Life Sciences
- Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown